March 31, 2025
The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen […]
March 28, 2025
The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without inhibitors. Fitusiran is a first-in-class small […]
March 28, 2025
TOPLINE: Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising […]
March 28, 2025
In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic […]
March 28, 2025
TOPLINE: High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a new trial showed. […]
March 28, 2025
TOPLINE: A higher body mass index (BMI) across all ages as well as significant weight gain during adulthood were associated with a greater risk for renal […]
March 27, 2025
For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic […]
March 27, 2025
TOPLINE: A mailed fecal immunochemical test (FIT) outreach followed by patient navigation for those with a positive test increased colorectal cancer (CRC) screening participation at 6 […]
March 27, 2025
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated […]